Great past: Advanced Biotechnology Industry and Research in the : Used to be extremely strong in tradional biotechnology: Crop and animal breeding fermentation industry Famous Brewery tradition Wine, ethanol, baker`s yeats production Fodder yeast (Biocel Paskov) Biotransformations: Aminoacid production, cyclosporin A, ergot alcaloids Vitamines, food additives etc. Peter Šebo Institute of Biotechnology Academy of Sciences of the Prague 1 Among pioneers of antibiotics production (penicilin) World famous school of continous culture technology (at Institute of Microbiology of the Academy of Sciences) 2 modest present: Selected biotech companies Prague somewhat behind in cutting edge biological research advanced biotech research is limited advanced biotech intellectual property limiting Small size of advanced biotech industry 6real biotech companies: Lonza, Baxter, Contipro, Exbio, BioVendor, Immunotech Immunotech (Beckman Coulter) immunodiagnostics Ascoprot Biotech SME (5 p.) rec. proteins BIOPREPARÁTY biological plant protection GeneAge Technologies expression profiling Genomac International sequencing/genotypinggenotyping LentiKat waste water treatment RD Top Bio molecular biol.kits producer SME (<5) Low numbers of high tech biotech SME thus far 3 Sel. biotech companies Central Bohemia Sel. biotech companies South Moravia Apronex SME, recombinant proteins (4 p) Baxter Czech flu vaccine production site Biologicals SME, forensics, HCV Y Screen EXBIO SME, Mab and reagent producer Lonza Biotec fermentation plant and RD FDA registered pharma enzymes Proteix SME, recombinant proteins (3 p) recoli SME, recombinant proteins VIDIA SME, clinical diagnostic kits BioTest drug and biologicals testing BioVendor SME, recombinant proteins, diagnostics Bioveta veterinary vaccines RD and production Enantis SME, recombinant dehalogenases contract research in protein engineering EPS SME, bioremediation, biogas Moravian Biotechnology SME, custom antibody services TEST LINE SME, human and veterinary diagnostics 1
Sel. biotech companies remaining regions GENERI BIOTECH SME, oligonucleotides, DNA genotyping services Contipro Group world leader in hyaluronic acid GMP recombinant defensins, wound healing RD BPMedical B.P.Medical SME, bioactivity testing ENVISAN GEM bioremediation GEN TREND SME, diagnostics and proteins AgroBio agrochemicals and agrobiologicals Biocel pulp industry fodder yeast producer IVAX Teva Pharmaceuticals, generics OlChemIm SME, phytohormones, antibodies (5 p) Promising future: Government recognizesthe problem Advanced biotechnology and molecular biology among strategic longterm research orientations funding schemes Good culture, education, enough PhDs, qualified manpower National applied research supportschemes schemes (NPV ) Incentives for Academia collaborations with Industry 4. 5 bil. Euro from ERDF funds for OP RD for Innovation and Enterprise for Innovation a fair portion of it going to biotech Institute of Biotechnology AS CR, v.v.i.. founded on January 1, 2008 BIOCEV, CEITEC, BioMedReg and several other major projects in preparation 8 University students vs. life science students: geographical distribution Academy of Sciences Basic Facts and Mission of the ASCR Leading basic research institution of CR Funded from state budget mainly ~6400 employees, >50% university graduates and PhDs Not a University Network of 60 institutes All transformed to Public Research Institutes by January 1, 2007 http://www.cas.cz/en 10 INSTITUTE OF MOLECULAR GENETICS AS CR Flemingovo nám. 2 Prague 6, CZ-16637 Phone: +420 220 183 111 Fax: +420 224 310 955 E-mail: img@img.cas.cz http://www.img.cas.cz Molecular Cell Biology Molecular Applied Immunology Molecular Genetics Recombinant proteins Monoclonal antibodies Cellular vaccines Monoclonal antibodies Unique mouse strains New Institute's building to completed in 2007 Developmental Biology Virology Unique chicken inbreds 2
Institute of Experimental Medicine (IEM) Prof. Eva Sykova, D.Sc. phone: +420 296 442 230 fax: +420 296 442 782 sykova@biomed.cas.cz cz http://uemweb.biomed.cas.cz Stem cell research at IEM iron nanoparticles for in vivo NMR imaging of stem cells Biodegradable hydrogels for stem cell ingrowth into hydrogel implants in spinal cord lesion reparation Growth of olfactory glial ensheathing cells Establishing and characterizing human embryonic stem cells (Dr. P. Dvorak in Brno among the world`s leaders) sykova@biomed.cas.cz http://uemweb.biomed.cas.cz Institute of Physiology Neurophysiology Centre of Cardiovascular Research Videnska 1083, 142 20 Prague 4-Krc, Phone: +420 2 9644 1111 Fax: +420 2 4106 2488 E-mail: fgu@biomed.cas.cz http://www.biomed.cas.cz/fgu/en/index.php Innovation of clinically used vascular prostheses: coating with extracellular matrix (ECM) molecules and endothelialization Inner surface On the inner surface, laminin or fibrin were immobilized - Bioartificial vascular tissue prostheses - Regionally-selective cell adhesion on micropatterned surface - Bone tissue engineering on nanostructured materials Endothelial cells grow and differentiate fgu@biomed.cas.cz Institute of Microbiology Institute of Microbiology microalgae cultivation biotechnology Biotechnological pilot plant Videnska 1083 CZ-142 20 Prague 4 phone: +420 296 442 341 fax: +420 296 442 201 e-mail: mbu@biomed.cas.cz http://www.biomed.cas.cz/mbu/en/ Targeted polymeric drugs Biotransformation of glycans Antigen delivery tools for immunotherapy and diagnostics http://www.biomed.cas.cz/mbu/en/ 3
Current status of antigen delivery technology 1997 - Protective immunity against a virus (LCMV) 1999 - Immunotherapy of transplanted tumors in mice 2004 - Enhanced detection of latent tuberculosis 2005 - Protective immunity against Plasmodium (mouse malaria model) 2005 - immunotherapy of experimental tumors (such as HPV16 induced) (US Patent No. 5,503,829, No. 5,679,784, No. 5,935,580, EU Patent application No. 03291486.3, US Prov 03495, 6094 (2003) ) preclinical data in vivo toxicological studies Phase III clinical trial in preparation for: melanoma (EU FP consortium THERAVAC) HPV16-induced cervical carcinoma (BT Pharm,a S.A. Toulouse France) http://l125lsx.mbu.cas.cz/lab125/ sebo@biomed.cas.czbiomed.cas.cz INSTITUTE OF EXPERIMENTAL BOTANY Cytokinins as cell-division-inhibiting substances for cancer treatment Sorted chromosomes for plant genomics Edible vaccines in plants Institute of Experimental Botany Rozvojová 135 165 00 Prague 6 - Lysolaje Phone: +420 220 390 453 Fax: +420 220 390 456 E-mail: machackova@ueb.cas.cz www.ueb.cas.cz Inhibitors of cyclin-dependent kinases (CDK) R-Roscovitine Roscovitine -(Seliciclib) R phase II of clinical trials for cancer Institute of Biotechnology CDK2 / roscovitine co-crystal -Multiple myeloma -B-cell Chronic Lymphocytic Leukemia - Mantle Cell Lymphoma. Founded by Academy of Sciences January 1, 2008 Phase II clinical trial for Non-Small Cell Lung Cancer treatment M. Strnad et.al. http://rustreg.upol.cz/ 22 2008: IBT M. Kubista J. Neužil J. Pěknicová R. Sedláček Š. Růžičková P. Šebo IBT seeding groups 2007 2010 2010 Single cell expression profiling Molecular and recombinant therapeutics Diagnostics for reproductive medicine Transgenic Animals Diagnostics of autoimmunediseases Recombinant binding proteins (ligands) syructural bioinformatics Šebo Recombinant binding proteins ( 2009: G. Pavlinkova C. Barinka gene expression regulation in diabetic embryopathy structural biology 20010 / 2011 Evaluation/new recruitements 2012 Recruitement of new groupleaders 2013 New BIOCEV center opens Promoting Czech biotech Catalyzed establishement of a Czech biotech company cluster CzechBio national association of advanced biotech industry Initiating a project of a Czech Biomanufacturing Centre (National center for GMP manufacturing of biological drugs for early stage clinical testing) 23 4
Establishing a CzechBio cluster Establishing a CzechBio cluster AppGenics s.r.o. Apronex s.r.o. Central Europian Biosystem s.r.o. Jihomoravské inovační centrum Contipro CPN Group, a.s. LentiKat s a.s. BVT Technologies, a.s. BTÚ About 60 companies targeted, 3 AS CR institutes, ICT Prague Ascoprot Biotech, s.r.o. Dyntec s.r.o. B.P.Medical spol. s.r.o. Baxter Czech spol. s r.o. Enantis s.r.o. ENVISAN GEM, a. s. Lonza Biotec, s.r.o. Protean s.r.o. Proteix s.r.o. Zentiva a.s. Klastr NATURPOL MERCI All major players responded On December 18th 2008 founded 20 members, more joining Biocel Paskov a.s. Exbio Praha a.s. SEVAPHARMA a.s. BIO SKIN, a.s. Specifying tasks and objectives Biologicals s.r.o Bionext Energy Europe s.r.o. BIOPHARM VÚ biofarmacie a veterinárních léčiv a.s. Biotest s.r.o. GEN TREND s.r.o. GENERI BIOTECH s.r.o. TATAA molecular diagnostics Technologický park Hořátev Genomac International, s.r.o. TEST LINE, Clinical Diagnostics, spol. s r.o. GENZYME EUROPE BV, organizační složka Top Bio, s.r.o. IVAX Pharmaceuticals s.r.o. GeneAge Technologies, a.s. ADW BIO, a.s. Biocel paskov a.s. Analysing case studies of successful clusters Appling for spport to OP EI Mingling session program for 2009 BioVendor Laboratorní medicína a.s. IMMUNOTECH, a.s. VIDIA spol. s r.o. VUAB a.s. Bioveta, a.s. 25 26 On December 20. 2007 the prime minister of CR assisted the signature of BIOCEV z.s.p.o. consortium agreement Biotech Biomed Research Center of Academy of Sciences and Charles University Vestec at Prague Regional development and competitiveness through promotion of cutting-edge biotechnology and biomedical RD in Shortlisted for funding from European Regional Development Fund Operational Program RD for Innovation 2007-2013 IBT AV ČR CU IEM IMIC IMG Academy of Sciences of CR Public research institutes: Institute of Biotechnology (established on 1.1.2008) Institute of Physiology Institute of Microbiology Institute of Experimental Medicine Institute of Macromolecular chemistry Institute of Molecular Genetics Charles University: Přírodovědecká fakulta 1. Lékařská fakulta Joint International Graduate School of molecular and cellular biotechnology OPERATIONAL PROGRAM RESEARCH AND DEVELOPMENT FOR INNOVATION PRIORITY AXIS 1:EUROPEAN CENTERS OF EXCELLENCE LOCATION: REGION OF CENTRAL BOHEMIA VESTEC TO BEBUILT 2010 2012 BUDGET : 114 MIL. WITHOUT START UP GRANT 131 MIL. WITH START UP GRANT Roadmap of BIOCEV March 2006 Basic parameters of BIOCEV Department of Biotechnology of the Institute of Molecular Genetics AS CR formed to lead the preparatory work of the BIOCEV project August 2007 5,5 ha of constructible land purchased by the Academy of Sciences for construction of BIOCEV in the industrial zone at Vestec December 2007 Consortium agreement of BIOCEV z.s.p.o.. signed in the presence of the prime minister of the January 2008 February 2008 March 2009 Institute of Biotechnology established by the Academy of Sciences on January 1, 2008 as a new public research institution legal entity, to serve for nucleation center of BIOCEV BIOCEV z.s.p.o. registered as a legal entity, Board leads project preparation BIOCEV project officially submitted for evaluation to the Ministry of Education, Youth and Sport of the Czech Republic October 2010 Start of BIOCEV infrastructure construction November 2010 October 2012 January 2013 recruiting and international call for applications for BIOCEV groupleader positions under auspices of the International scientific advisory board of BIOCEV Heavy equipment technologies installation at the new BIOCEV campus, research groups moving into new BIOCEV buildings BIOCEV full operation 5
Phase I 50 employees 2007-2011 at Prague-Krc - Lb Bldg. Phase II 2012 new BIOCEV Bldg. at Vestci near Prague AS CR purchased 55 000 m 2 of constructible land 400 450 employees and postdocs 30 45research groups + 150 visiting researchers, students = 600 people Why at Vestec? BIOCEV Czech advanced Biotech research and industry hub Biotech park A possible look of BIOCEV Activities of BIOCEV v.v.i. National BiotechBiomed Research Infrastructure International School of advanced studies in biotechnology and biomedicine MOUSE CLINIC INFRAFRONTIER National mammalian model phenotyping, genome mining archiving infrastructure STRUCTURAL BIOLOGY INSTRUCT National Structural Biology Infrastructure OMICS Infrastructure GRADUATE EDUCATION BASIC RESEARCH IMAGING Molecular Genetics Cell Biology National Immunology Tumor Biology Biological Imaging Core facility Eukaryotic Microbiology Protein and Cell Biomaterials and Tissue Engineering Methods development ORIENTED RESEARCH Protection of Intellectual property Technology transfer Business development CELL CULTURE National Protein Expression and Purification facility Cryotechnologies Biobanking facility Aim: integration into European Research Area European strategic research infrastructures ESFRI INFRAFRONTIERS Czech Mouse Clinic - Center of knock-in/knock-out mouse phenotyping ESFRI EuroBioImaging Optical and electron imagingi Open-access equipments of BIOCEV Cutting-edge mass spectrometry for top-down protein modification analysis (FT-MS ion cyclotron 15T) Animal transgenesis unit mammalian cell culture facility Recombinant protein purification facility IT and data storage Biobank? and cryo repository? Czech Center for Phenogenomics Man and mouse share 95% of highly similar genes 30 000 knock-out mouse strains in preparation - gene after gene What does which gene do Mouse clinic examinations: - pathologies - imunology resistance to infection - clinical biochemistry - metabolism - cardiology - neurology - behaviour - growth defects - perception vision, hearing, smell - genome expression 6
Planing for transgenic animal disease models Protein and cell engineering Targeted biological - protein drugs against cancer, pain, arthritis hritis, osteoporosis osis Engineering tissue prostheses Biomaterialsals for tissue engineering Artifical bones from cells grown on porous scaffolds Vascular prostheses colonized by endothelial cells Biology of tumor cells Contact: sebo@biomed.cas.cz Peter Sebo, PhD. Institute of Biotechnology AS CR, v.v.i. Academy of Sciences of the Videnska 1083 142 20 Prague 4 Tumor cell penetrating bone marrow How to defeat them Breast carcinoma cell GSM: (+420) 774 798 121 office: (+420) 241 062 762 http://www.ibt.cas.cz 7